Response Evaluation Criteria in Prostate-specific Membrane Antigen (PSMA) PET/CT 1.0

**Semantic type:** Intellectual Product

**Definition:** A quantitative assessment that combines changes in the prostate-specific membrane antigen (PSMA)-positive total tumor volume (TTV) and the occurrence of new lesions. It was developed in 2022 to evaluate treatment response using PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (Gafita A, Rauscher I, Weber M, et al. Novel framework for treatment response evaluation using PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. J Nucl Med 2022;63(11):1651-1658).

**Synonyms:** - RECIP 1.0 - Response Evaluation Criteria in PSMA-PET/CT Version 1.0 - Response Evaluation Criteria in PSMA-PET/CT Version 1.0